Sedation During Pediatric Diagnostic Gastrointestinal Endoscopy Gastrointestinal Endoscopy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03235609|
Recruitment Status : Unknown
Verified August 2017 by Mohamed galal aly, Assiut University.
Recruitment status was: Not yet recruiting
First Posted : August 1, 2017
Last Update Posted : August 3, 2017
|Condition or disease||Intervention/treatment||Phase|
|Sedation||Drug: Fentanyl Drug: Ketamine||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Masking Description:||double blind|
|Official Title:||Propofol-Ketamine vs. Propofol-Fentanyl for Sedation During Pediatric Diagnostic Gastrointestinal Endoscopy|
|Estimated Study Start Date :||August 16, 2017|
|Estimated Primary Completion Date :||June 15, 2018|
|Estimated Study Completion Date :||August 15, 2018|
Active Comparator: Fentanyl
Group I (FP): will receive 0.5 µg/ kg fentanyl + 2 mg/ kg propofol IV.
fentanyl used with propofol for sedation
Other Name: Fentanyl Citrate
Active Comparator: Ketamine
Group II (KP): will receive 0.5 mg/kg ketamine + 2 mg/kg propofol IV.
ketamine used with propofol for sedation
Other Name: katalar
- incidence of desaturation [ Time Frame: up to 2 days after operation ]when oxygen saturation below 90%
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03235609
|Contact: Mohamed Alyfirstname.lastname@example.org|